【藥品庫存】 停換藥：本品因廠商缺貨，關檔停用，請以同成分同規格藥品 RIV02 【G1】高 Rivotril 錠劑 2mg替代。更新日期：2022/5/27。

鎮靜安眠、癲癇治療
Panic disorder: Treatment of panic disorder, with or without agoraphobia
Seizure disorders: Treatment of the Lennox-Gastaut syndrome, akinetic, and myoclonic seizures; absence seizures unresponsive to succinimides

Antiseizure Agent; Benzodiazepine
The exact mechanism is unknown, but believed to be related to its ability to enhance the activity of GABA; suppresses the spike-and-wave discharge in absence seizures by depressing nerve transmission in the motor cortex.

Absorption:
1. Rapidly and completely absorbed.
2. Onset of action: ~20 to 40 minutes.
3. Duration: (Infants and young children) 6 to 8 hours; (Adults) ≤12 hours
4. Bioavailability: ~90%
5. Time to peak, serum: 1 to 4 hours
Distribution:
1. Vd: (Children) 1.5 to 3 L/kg; (Adults) 1.5 to 6.4 L/kg
2. Protein binding: ~85%
Metabolism:
1. Extensively hepatic via glucuronide and sulfate conjugation; undergoes nitroreduction to 7-aminoclonazepam, followed by acetylation to 7-acetamidoclonazepam; nitroreduction and acetylation are via CYP3A4; metabolites undergo glucuronide and sulfate conjugation
2. Half-life elimination: (Neonates) 22 to 81 hours; (Children) 22 to 33 hours; (Adults) 17 to 60 hours
Excretion:
Urine (<2% as unchanged drug); metabolites excreted as glucuronide or sulfate conjugates

1. Hypersensitivity to benzodiazepines
2. Patients with significant liver disease
3. Patients with acute narrow angle glaucoma

D

1. According to the manufacturer, the decision to breastfeed during therapy should consider the risk and benefits.
2. If chronic use of a benzodiazepine is needed in breastfeeding females, use of shorter acting agents is preferred.

Drowsiness, aphonia, confusion, depression, ataxia, increased salivation, constipation, diarrhea, nausea, dry mouth, respiratory depression, thrombocytopenia

Anxiety disorder:
1. Initial: 0.25 to 1 mg/day in 1 to 2 divided doses; may be given as needed or scheduled
2. Adjustment: May increase daily dose in increments of 0.25 to 0.5 mg every few days (eg, ≥3 days); usual target range: 1 to 3 mg/day in 1 to 4 divided doses; maximum: 4 mg/day
3. Administration: To minimize daytime motor impairment and drowsiness, may be taken as a single dose at bedtime
Seizure disorders:
1. Monotherapy: Initial 0.5 to 1.5 mg/day in 1 to 3 divided doses
2. Adjunctive therapy: Initial 0.5 to 1 mg/day in 1 to 3 divided doses
3. Dosage adjustment: May increase dose based on response and tolerability in increments of 0.5 to 1 mg every 3 to 7 days to usual maintenance dose of 2 to 8 mg/day in 1 to 2 divided doses; maximum dose: 20 mg/day

Anxiety disorder: (for Adolescents ≥18 years)
1. Initial: 0.25 mg twice dailiy; increase in increments of 0.125 to 0.25 mg twice daily every 3 days; target 1 mg/day in divided doses; maximum 4 mg/day
2. To discontinue, treatment should be withdrawn gradually; decrease dose by 0.125 mg twice daily every 3 days until medication is completely withdrawn.
Seizure disorders: (In Infants and Children <10 years or ≤30 kg)
1. Initial: 0.01 to 0.03 mg/kg/day in 2 to 3 divided doses; maximum 0.05 mg/kg/day; increase by ≤0.25 to 0.5 mg every third day until seizures are controlled or adverse effects observed
2. Maintenance: 0.1 to 0.2 mg/kg/day in 3 divided doses; maximum 0.2 mg/kg/day
Seizure disorders: (In Children ≥10 years or >30 kg and Adolescents)
1. Initial: 0.01 to 0.05 mg/kg/day in 2 or 3 divided doses; maximum 0.5 mg/dose 3 times daily; may increase dose by 25% or by 0.5 to 1 mg every 3 to 7 days until seizures are controlled or adverse effects observed
2. Maintenance: 0.05 to 0.2 mg/kg/day in 2 to 3 divided doses; maximum 20 mg/day

1. Altered kidney function: Initial: No dosage adjustment necessary for any degree of kidney impairment
2. Hemodialysis, Peritoneal dialysis: Unlikely to be substantially dialyzed (highly protein bound, large Vd); Titrate based on tolerability and response
3. CRRT, PIRRT: No dosage adjustment necessary; Titrate based on tolerability and response

1. There are no dosage adjustments provided in the manufacturer's labeling; use with caution.
2. Contraindicated in patients with significant hepatic impairment.